How and where to order Warfarin Sodium (Coumadin) 1 mg, 2 mg, 5 mg tablets or capsules online on the National Blood Data Resource Center website:
|Prices:||from $0.23 per pill
|Discount:||10% coupon: DFHDCC
|Forms:||Coumadin (Warfarin Sodium) 1 mg, 2 mg, 5 mg tablets
|Type:||Warfarin brand, Coumadin generic
|Payment:||PayPal, Visa, MasterCard, AmEx, E-Check (ACH), Bitcoin
|Delivery:||Regular and express mail service
|Shipping:||Worldwide, including USA, UK, Europe, Canada, Australia
Warfarin (trade names include Coumadin, Jantoven, Maforan, Apo-Warfarin, Marevan, Orfarin, Taro-Warfarin, Waran, Warf) is an antithrombotic agent from Vitamin K antagonists pharmacological group. This medication is used as anticoagulant for the treatment of blood clots such as first and recurrent events of pulmonary embolism, deep vein thrombosis, heart attack, heart failure, antiphospholipid syndrome, chronic central venous catheterization, ST-segment elevation myocardial infarction (STEMI), protein S deficiency, for orthopedic surgery, to prevent thrombosis, thromboembolism and stroke in people who have atrial fibrillation, valvular heart disease or artificial heart valves, for prophylaxis of deep vein thrombosis after hip replacement surgery, knee replacement surgery. It works as blood thinner by inhibiting the vitamin K-dependent synthesis of biologically active forms of the clotting factors.
Acetylsalicylic Acid (Aspirin)
Aspirin, Dipyridamole (Aggrenox)
Eplerenone (Inspra, Planep)
Isosorbide Dinitrate (Isordil)
Pharmacological and medical categories:
Anti thrombosis medicines
B - Blood and blood forming organs
B01 - Antithrombotic agents
B01A - Antithrombotic agents
B01AA - Vitamin K antagonists
B01AA03 - Warfarin
Other coagulation defects - D68
Other primary thrombophilia - D68.59
Antiphospholipid syndrome - D68.61
Acute myocardial infarction - I21
ST elevation (STEMI) myocardial infarction of unspecified site - I21.3
Pulmonary embolism - I26
Endocarditis, valve unspecified - I38
Atrial fibrillation and flutter - I48
Heart failure - I50
Complications and ill-defined descriptions of heart disease - I51
Cerebral infarction - I63
Arterial embolism and thrombosis - I74
Embolism and thrombosis of unspecified artery - I74.9
Other venous embolism and thrombosis - I82
Acute embolism and thrombosis of unspecified vein - I82.90
Complications following infusion, transfusion and therapeutic injection - T80
Orthopedic aftercare - Z47
Presence of cardiac and vascular implants and grafts - Z95
Presence of prosthetic heart valve - Z95.2
Presence of other functional implants - Z96
Presence of right artificial hip joint - Z96.641
Presence of right artificial knee joint - Z96.651
Indications and usage:
Coumadin (Warfarin Sodium) is a vitamin K antagonist indicated for:
Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism.
Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement.
Reduction in the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
Limitations of use
Coumadin has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage.
Dosage and administration:
Individualize dosing regimen for each patient, and adjust based on INR response.
Knowledge of genotype can inform initial dose selection.
Monitoring: obtain daily INR determinations upon initiation until stable in the therapeutic range. Obtain subsequent INR determinations every 1 to 4 weeks.
Review conversion instructions from other anticoagulants.
Dosage forms and strengt:
Coumadin (Warfarin Sodium) scored tablets: 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg, 10 mg.
Signs and symptoms
Bleeding (e.g., appearance of blood in stools or urine, hematuria, excessive menstrual bleeding, melena, petechiae, excessive bruising or persistent oozing from superficial injuries, unexplained fall in hemoglobin) is a manifestation of excessive anticoagulation.
The treatment of excessive anticoagulation is based on the level of the INR, the presence or absence of bleeding, and clinical circumstances. Reversal of Coumadin anticoagulation may be obtained by discontinuing warfarin therapy and, if necessary, by administration of oral or parenteral vitamin K1.
The use of vitamin K1 reduces response to subsequent Coumadin (Warfarin) therapy and patients may return to a pretreatment thrombotic status following the rapid reversal of a prolonged INR. Resumption of this medication administration reverses the effect of vitamin K, and a therapeutic INR can again be obtained by careful dosage adjustment. If rapid re-anticoagulation is indicated, heparin may be preferable for initial therapy.
Prothrombin complex concentrate (PCC), fresh frozen plasma, or activated Factor VII treatment may be considered if the requirement to reverse the effects of Coumadin is urgent. A risk of hepatitis and other viral diseases is associated with the use of blood products; PCC and activated Factor VII are also associated with an increased risk of thrombosis. Therefore, these preparations should be used only in exceptional or life-threatening bleeding episodes secondary to Warfarin Sodium overdosage.
Pregnancy, except in women with mechanical heart valves.
Hemorrhagic tendencies or blood dyscrasias.
Recent or contemplated surgery of the central nervous system (CNS) or eye, or traumatic surgery resulting in large open surfaces.
Bleeding tendencies associated with certain conditions.
Threatened abortion, eclampsia, and preeclampsia.
Unsupervised patients with potential high levels of non-compliance.
Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding.
Hypersensitivity to warfarin or any component of the product.
Major regional or lumbar block anesthesia.
Warnings and precautions:
Tissue necrosis: necrosis or gangrene of skin or other tissues can occur, with severe cases requiring debridement or amputation. Discontinue Coumadin (Warfarin Sodium) and consider alternative anticoagulants if necessary.
Calciphylaxis: fatal and serious cases have occurred. Discontinue Coumadin and consider alternative anticoagulation therapy.
Acute kidney injury may occur during episodes of excessive anticoagulation and hematuria.
Systemic atheroemboli and cholesterol microemboli: some cases have progressed to necrosis or death. Discontinue warfarin if such emboli occur.
Heparin-induced thrombocytopenia (HIT): initial therapy with Coumadin in HIT has resulted in cases of amputation and death. Warfarin may be considered after platelet count has normalized.
Pregnant women with mechanical heart valves: Warfarin Sodium (Coumadin) may cause fetal harm; however, the benefits may outweigh the risks.
Adverse reactions, side effects:
Most common adverse reactions to warfarin are fatal and nonfatal hemorrhage from any tissue or organ.
To report suspected adverse reactions of Coumadin (Warfarin Sodium) tablets, contact Bristol-Myers Squibb pharmaceutical company or your local FDA.
Concomitant use of drugs that increase bleeding risk, antibiotics, antifungals, botanical (herbal) products, and inhibitors and inducers of CYP2C9, 1A2, or 3A4.
Consult labeling of all concurrently used drugs for complete information about interactions with Coumadin or increased risks for bleeding.
Use in specific populations:
Pregnant women with mechanical heart valves: Coumadin (Warfarin) may cause fetal harm; however, the benefits may outweigh the risks.
Lactation: monitor breastfeeding infants for bruising or bleeding.
Renal impairment: instruct patients with renal impairment to frequently monitor their INR.
D - Australia
X - United States (Should not be used during pregnancy)
Salts and other forms:
Warfarin Sodium Clathrate
Synonyms, international and chemical names:
Brands, generics, trade names:
Aldocumar - Aldo Union
Apo-Warfarin - Apotex, Hind Wing, Pharmaforte
Coumadin - Bristol-Myers Squibb
Jantoven - USL Pharmaceuticals
Maforan - Sriprasit
Marevan - GlaxoSmithKline
Orfarin - Orion Pharma
Panwarfin - Abbott
Sofarin - Teva, Samarth Pharma
Taro-Warfarin - Taro Pharmaceutical Industries
Waran - Nycomed
Warf - Cipla
Warfarin - Sandoz, Teva, Watson Pharmaceuticals
Here is a list of popular medications containing warfarin as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:
|Trade name of the drug
||Pharmaceutical forms and doses
||Injectable; Injection; Warfarin Sodium 5 mgInjectable; Injection; Warfarin Sodium 50 mgInjectable; Injection; Warfarin Sodium 75 mgTablets; Oral; Warfarin Sodium 1 mgTablets; Oral; Warfarin Sodium 2 mgTablets; Oral; Warfarin Sodium 2.5 mgTablets; Oral; Warfarin Sodium 3 mgTablets; Oral; Warfarin Sodium 4 mgTablets; Oral; Warfarin Sodium 5 mgTablets; Oral; Warfarin Sodium 6 mgTablets; Oral; Warfarin Sodium 7.5 mgTablets; Oral; Warfarin Sodium 10 mg
||Bristol-Myers SquibbB. BraunBootsHealthcare LogisticsInvidaSanofiSigma PharmaceuticalsTaro Pharmaceutical IndustriesZentivaZuellig PharmaZuoz Pharma
||Tablets; Oral; Warfarin Sodium 1 mgTablets; Oral; Warfarin Sodium 3 mgTablets; Oral; Warfarin Sodium 5 mg
||GlaxoSmithKlineBootsFarmoquimicaGoldshield PharmaceuticalsInstitute of Pharmaceutical Research and TechnologyNycomedOrion PharmaSigma PharmaceuticalsTherabel PharmaZuellig Pharma
||Tablets; Oral; Warfarin Sodium 3 mgTablets; Oral; Warfarin Sodium 5 mg
||Orion PharmaApex PharmacyHarn Thai PharmaPharmaconRigel Pharma
Warfarin main article on Wikipedia: https://en.wikipedia.org/wiki/Warfarin
Warfarin compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Warfarin
Warfarin Sodium compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Warfarin-sodium
Warfarin on DrugBank: https://go.drugbank.com/drugs/DB00682
Warfarin Sodium on DrugBank: https://go.drugbank.com/salts/DBSALT000278
Warfarin FAQ on MedlinePlus (revised 06/15/2017): https://medlineplus.gov/druginfo/meds/a682277.html
Taking Warfarin (Coumadin) FAQ on MedlinePlus (revised 01/28/2019): https://medlineplus.gov/ency/patientinstructions/000292.htm
Blood thinners (anti-platelet drugs, anticoagulants) review on MedlinePlus: https://medlineplus.gov/bloodthinners.html
Warfarin Sodium tablets drug label info on DailyMed (revised December 29, 2020): https://dailymed.nlm.nih.gov/dailymed/drugInfo...
Coumadin (Warfarin Sodium) tablets drug label info on DailyMed (revised August 14, 2012): https://dailymed.nlm.nih.gov/dailymed/drugInfo...
Warfarin containing drugs on Drugs-About.com: https://drugs-about.com/ing/warfarin.html
Warfarin for sale on Pharma Doctor: https://pharma-doctor.com/warfarin.html
Warfarin international drug names on Drugs.com: https://www.drugs.com/international/warfarin.html
Coumadin (Warfarin Sodium) tablets for oral use and injections for intravenous use official prescribing information and medication guide from the U.S. FDA (revised 10/2011): https://www.accessdata.fda.gov/drugsatfda_docs/label...
Coumadin (Warfarin Sodium) tablets for oral use prescribing information and medication guide from Bristol-Myers Squibb pharmaceutical company (revised 12/2019): https://packageinserts.bms.com/pi/pi_coumadin.pdf
Marevan (Warfarin Sodium) tablets prescribing information from the Therapeutic Goods Administration (revised 16/03/2020): https://www.ebs.tga.gov.au/ebs/picmi/...
Marevan (Warfarin Sodium) tablets consumer medicine information from the Therapeutic Goods Administration (revised March 2020): https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/...
Orfarin (Warfarin Sodium) tablets prescribing information from MIMS: https://www.mims.com/thailand/drug/info/orfarin?type=full
Sun Pharma Warfarin Sodium 0.5 mg, 1 mg, 3 mg, 5 mg tablets patient information leaflet on Medicines.org.uk (revised 07/2020): https://www.medicines.org.uk/emc/files/pil.3064.pdf
Revised: June 2021
Home | About Us | Research | Membership | Products & Services | FAQs | Contact Us
Copyright © 2000 - 2021 National Blood Data Resource Center. All rights reserved.